Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.32 -0.5%	$8.94	$6.38 ▼ $17.30	$906.44M	1.45	1.27 million shs	1.27 million shs
NRIX Nurix Therapeutics	$11.62 +2.0%	$10.75	$8.18 ▼ $29.56	$868.32M	2.15	863,306 shs	491,613 shs
NTLA Intellia Therapeutics	$9.60 +0.2%	$8.24	$5.90 ▼ $28.18	$992.32M	2.14	2.88 million shs	5.76 million shs
TVGN Semper Paratus Acquisition	$1.20 -1.6%	$1.15	$0.26 ▼ $3.09	$224.35M	-0.69	5.05 million shs	371,487 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.53%	-5.76%	-0.32%	+7.50%	-40.26%
NRIX Nurix Therapeutics	+2.02%	-8.00%	+22.19%	-16.22%	-36.98%
NTLA Intellia Therapeutics	+0.21%	+14.70%	+5.96%	+10.34%	-61.29%
TVGN Semper Paratus Acquisition	-1.64%	-10.45%	+4.35%	+2.56%	+50.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.2186 of 5 stars	3.5	1.0	0.0	2.7	1.7	0.6
NRIX Nurix Therapeutics	1.3632 of 5 stars	3.4	1.0	0.0	1.7	0.8	0.0
NTLA Intellia Therapeutics	4.4577 of 5 stars	4.3	1.0	4.7	2.4	2.5	0.6
TVGN Semper Paratus Acquisition	3.9988 of 5 stars	3.5	4.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	94.92% Upside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	159.69% Upside
NTLA Intellia Therapeutics	2.67	Moderate Buy	$34.95	264.06% Upside
TVGN Semper Paratus Acquisition	3.00	Buy	$7.10	491.67% Upside

Current Analyst Ratings Breakdown

Latest TVGN, NTLA, AVDL, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/3/2025	NTLA Intellia Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $54.00
5/29/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00 ➝ $7.00
5/29/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/27/2025	TVGN Semper Paratus Acquisition	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/20/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/19/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00 ➝ $10.00
5/12/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $45.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	5.33	N/A	N/A	$0.77 per share	12.10
NRIX Nurix Therapeutics	$54.55M	16.24	N/A	N/A	$7.44 per share	1.56
NTLA Intellia Therapeutics	$57.88M	17.18	N/A	N/A	$8.56 per share	1.12
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	155.33	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
TVGN Semper Paratus Acquisition	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-934.56%	8/4/2025 (Estimated)

Latest TVGN, NTLA, AVDL, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Semper Paratus Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
NRIX Nurix Therapeutics	N/A	6.26	6.26
NTLA Intellia Therapeutics	N/A	4.90	4.90
TVGN Semper Paratus Acquisition	N/A	0.35	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
NRIX Nurix Therapeutics	N/A
NTLA Intellia Therapeutics	88.77%
TVGN Semper Paratus Acquisition	N/A

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
NRIX Nurix Therapeutics	7.40%
NTLA Intellia Therapeutics	3.10%
TVGN Semper Paratus Acquisition	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	92.10 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
TVGN Semper Paratus Acquisition	3	183.89 million	49.21 million	N/A

TVGN, NTLA, AVDL, and NRIX Headlines

Recent News About These Companies

Semper Paratus Acquisition's (TVGN) "Buy" Rating Reaffirmed at D. Boral Capital

June 18 at 9:36 AM | marketbeat.com

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

June 18 at 8:30 AM | globenewswire.com

Tevogen Bio

June 17 at 11:45 AM | thepharmaletter.com

Tevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars Initiatives

June 12, 2025 | nasdaq.com

Tevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral Capital

June 11, 2025 | americanbankingnews.com

Tevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from Microsoft

June 10, 2025 | nasdaq.com

Tevogen Bio doubles Warren HQ footprint for AI expansion

June 10, 2025 | njbiz.com

Ambitious Tevogen makes expansion announcement

June 10, 2025 | thepharmaletter.com

Tevogen Bio (NASDAQ:TVGN) Given "Buy" Rating at D. Boral Capital

June 10, 2025 | marketbeat.com

Ryan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Stock

June 10, 2025 | insidertrades.com

Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) CEO Sells 1,438,206 Shares of Stock

June 9, 2025 | marketbeat.com

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

June 9, 2025 | globenewswire.com

tevogen bio expands office lease in new jersey with key amendment

June 5, 2025 | investing.com

Tevogen Bio breidt kantoorruimte uit in New Jersey met belangrijke wijziging

June 4, 2025 | nl.investing.com

Tevogen Bio breidt AI-initiatief uit voor ontwikkeling immunotherapie

June 1, 2025 | nl.investing.com

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Sees Significant Drop in Short Interest

June 1, 2025 | marketbeat.com

Tevogen Bio Holdings Inc. Unveils Tevogen.AI™ Initiative to Enhance Immunotherapy Development with Advanced AI Technologies

May 30, 2025 | quiverquant.com

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Earns "Buy" Rating from D. Boral Capital

May 28, 2025 | marketbeat.com

Tevogen Peports Plans to Increase the Target Population for TVGN 489

May 26, 2025 | msn.com

Tevogen expands target for COVID treatment to seniors

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVGN, NTLA, AVDL, and NRIX Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.32 -0.05 (-0.53%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.32 0.00 (0.00%)

As of 06/18/2025 04:33 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Nurix Therapeutics NASDAQ:NRIX

$11.62 +0.23 (+2.02%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.62 +0.01 (+0.04%)

As of 06/18/2025 04:39 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Intellia Therapeutics NASDAQ:NTLA

$9.60 +0.02 (+0.21%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.30 -0.31 (-3.18%)

As of 06/18/2025 07:59 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Semper Paratus Acquisition NASDAQ:TVGN

$1.20 -0.02 (-1.64%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.23 +0.03 (+2.08%)

As of 06/18/2025 06:44 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time